IDT Biologika Amplifies Global Role via Strategic CDMO Alliances

In a significant move to bolster its global presence, IDT Biologika, a Contract Development and Manufacturing Organization (CDMO) based in Germany and a subsidiary of SK bioscience, is intensifying its search for new business opportunities through its participation in major international biotechnology events. This strategy not only enhances its engagement with potential partners but also positions the company at the forefront of the biopharmaceutical industry.

Recent Events Highlighting IDT’s Capabilities

Recently, IDT Biologika showcased its extensive range of services at the BioProcess International Europe (BPI Europe) conference, held at the Congress Center Hamburg from May 12 to 15. BPI Europe stands as one of the premier platforms for bioindustry leaders, facilitating discussions on the latest technological advancements and emerging partnerships across the biopharmaceutical value chain. At the conference, IDT presented its tailored end-to-end services focused on the development and manufacturing of viral vaccines, gene therapies, and sterile injectables. The company highlighted successful collaboration stories that underscore its proven track record in the field.

Prominent figures from the company, such as Chief Commercial Officer Federico Pollano and Senior Expert in Business Development Dr. Nanette Schlatermund, were present at this vital event to explore potential collaborations in next-generation biopharmaceutical development. Their attendance reflects IDT's commitment to being actively involved in shaping the future of molecular medicine and vaccine production.

Engaging Globally and Building Networks

Earlier in the year, IDT Biologika participated in several key global events designed to foster dialogue regarding market trends and collaborative opportunities. In March, the company engaged with industry leaders during the DCAT Week 2025 in New York City—a notable networking event for stakeholders in the pharmaceutical sector that has been a cornerstone of the industry since 1890. IDT dedicated valuable time to high-level discussions focused on potential strategic alliances, engaging with senior leadership during the event.

Following closely, IDT Biologika took part in the World Vaccine Congress 2025 in Washington, D.C., held in April, where it underscored its advanced CDMO capabilities to international vaccine experts and public health personnel. The company notably presented its successful scale-up experience leveraging the iCELLis 500 platform, a sophisticated bioreactor technology for large-scale manufacturing—which reflects IDT's innovation in producing high-quality medicines.

Future Engagements and Strategic Growth

Looking ahead, IDT Biologika is poised to attend the BIO International Convention in Boston, scheduled for June 16 to 19. This event represents the largest gathering of biotechnology stakeholders globally and serves as another opportunity for IDT to reinforce its standing within the industry.

The transition of IDT Biologika into a global leader in the CDMO space has been significantly supported by its acquisition by SK bioscience last year. With over a century of expertise, IDT is well-equipped to cater to the needs of multinational pharmaceutical corporations and governmental health institutions across North America, Europe, and Asia. The company has recorded positive earnings in both Q4 2024 and Q1 2025, further stabilizing its financial standing within SK bioscience’s portfolio. With ambitious targets set for the year, IDT aims to generate over KRW 410 billion (approximately USD 294.86 million) in revenue, while additionally prioritizing profitability through enhanced operational efficiencies and new business endeavors.

Dr. Sally Choe, Co-CEO of IDT Biologika, reiterated the company's determination to drive global growth: “Our achievements in technology and reliability have been recognized through the CDMO Leadership Awards 2025, where we emerged as the winner in the Biologics – International category. We are committed to expanding our global outreach, leveraging distinct, customer-focused services alongside our extensive partnership experience.”

About SK bioscience

SK bioscience stands out as an innovative player within the vaccine and biotech sectors, fully committed to developing and manufacturing vaccines to ensure equitable access worldwide. By harnessing cutting-edge technologies, the company strives to enhance human health from prevention to treatment, collaborating with various stakeholders, including governments and health officials, to provide high-quality vaccines and improve public health solutions. For further information on their initiatives, visit the SK bioscience website or check their LinkedIn page for updates.